MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · IEX Real-Time Price · USD
2.690
+0.230 (9.35%)
Apr 24, 2024, 3:57 PM EDT - Market closed
Company Description
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer.
The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Vlad Vitoc M.B.A., M.D. |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
| Phone | 312-416-8592 |
| Website | MAIABiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Jeffrey C. Himmelreich | Head of Finance |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Apr 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 16, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 424B5 | Filing |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 13, 2024 | 8-K | Current Report |